Logo

GPC Biotech Licenses IP from Ariad

Feb 04, 2003

NEW YORK, Feb. 4 - GPC Biotech of Martinsried, Germanyhas non-exclusively licensed patents from Ariad pharmaceuticals in the area of cell-signaling regulation technology, the company said today.

 

This additional IP allows the company to add this technology to its LeadCode drug discovery platform, a modified yeast two-hybrid proteomics methodology that screens for interactions between a small molecule and the full complement of human proteins.

 

This new IP licensing agreement follows on the heels of GPC's collaboration with Eli Lilly Jan. 31 to use LeadCode for mechanism of action studies on a class of metabolic disease lead compounds.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.